Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients with normal fractional flow reserve and coronary microvascular disease
| العنوان: | Effect of Shexiang Tongxin dropping pill on stable coronary artery disease patients with normal fractional flow reserve and coronary microvascular disease |
|---|---|
| المؤلفون: | Yanbo Zhao, Jiefang Zhang, Junhui Zhu, Guosheng Fu, Xiaopeng Chu, Yanli Lu, Fu-yu Qiu, Chongying Jin |
| المصدر: | Medicine |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Coronary Artery Disease, Fractional flow reserve, law.invention, Coronary artery disease, 03 medical and health sciences, Coronary circulation, 0302 clinical medicine, Randomized controlled trial, Study Protocol Clinical Trial, law, Coronary Circulation, Internal medicine, medicine, Clinical endpoint, Humans, Prospective Studies, 030212 general & internal medicine, Myocardial infarction, Prospective cohort study, Randomized Controlled Trials as Topic, business.industry, Microcirculation, General Medicine, medicine.disease, coronary microvascular disease, Fractional Flow Reserve, Myocardial, Clinical trial, medicine.anatomical_structure, stable coronary artery disease, 030220 oncology & carcinogenesis, Microvessels, Shexiang Tongxin dropping pill, Cardiology, business, Drugs, Chinese Herbal, Research Article, study protocol |
| الوصف: | Introduction: Coronary microvascular disease (CMVD) can affect the structure, function, and metabolism of the heart, and has an important impact on the occurrence, development and prognosis of coronary artery disease (CAD). Shexiang Tongxin dropping pill (STDP) can dilate blood vessels, alleviate inflammation, reduce endothelial damage, and improve coronary microvascular function in mice with myocardial infarction. This study aims to assess the impact of STDP on stable coronary artery disease (SCAD) patients with normal FFR and CMVD. Methods and analysis: This is a single-center, prospective randomized trial that will enroll 64 SCAD patients, CAD with normal FFR and CMVD. Patients will be randomly divided into study group and control group in a 1:1 fashion. On the basis of conventional drug treatment, the former will receive STDP while the latter will not. The follow-up period of the subjects is 12 months, and clinical follow-up will be conducted before discharge, 30 days, 3 months, 6 months, and 12 months after procedure to complete the detection of relevant indicators. The primary endpoint is the change of index of microcirculatory resistance (ΔIMR) at 12-month follow-up. Discussion: The present study will be the first randomized control study to evaluate the efficacy and safety of STDP on SCAD patients, CAD with normal FFR and CMVD, which will provide a broader idea and more experimental basis for improving the treatment of CMVD. Trial registration: This is a protocol for the randomized clinical trial which has been registered in the Chinese clinical Trial Registry with an identifier: ChiCTR2000032429. |
| تدمد: | 1536-5964 0025-7974 2000-0324 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54e604d29d81b39f24c00383e98d5d40Test https://doi.org/10.1097/md.0000000000022126Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....54e604d29d81b39f24c00383e98d5d40 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15365964 00257974 20000324 |
|---|